Kinfo
Centessa Pharmaceuticals plc American Depositary Receipt logo

Centessa Pharmaceuticals plc American Depositary Receipt

CNTANASDAQHealthcare·US · USD
$40.50
+0.00 (+0.00%)
Prices as of June 29, 2026 · market closed

Price

Key statistics

Valuation
Market cap6.27B USD
Enterprise value6.11B USD
Trailing P/E-27.74
Forward P/E-22.75
PEG ratio-0.17
Price / sales417.77
Price / book12.86
Profitability
Gross margin0.00%
Operating margin-1228.36%
Profit margin0.00%
Return on assets-27.43%
Return on equity-57.38%
Income (TTM)
Revenue15.00M USD
Gross profit0.00 USD
EBITDA-256.34M USD
Net income-250.64M USD
Diluted EPS-$1.78
Rev. growth (YoY)0.00%
Balance sheet
Total cash276.59M USD
Total debt118.56M USD
Debt / equity24.33
Current ratio9.53
Book value / share$3.15
Cash flow (TTM)
Operating cash flow-208.80M USD
Levered free cash flow-128.72M USD
Shares & price
Shares outstanding154.73M
Float92.48M
Held by institutions96.93%
Beta1.12
50-day MA$39.77
200-day MA$29.97
52-week high$40.56
52-week low$15.01
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-07-180.390.38−2.56%2026-05-05-0.41-0.52−26.83%2026-03-31-0.38-0.48−26.32%2025-11-13-0.500.13+126.00%2025-11-05-0.39-0.41−5.13%
About Centessa Pharmaceuticals plc American Depositary Receipt

Centessa Pharmaceuticals plc American Depositary Receipt represents shares in Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company headquartered in Altrincham, United Kingdom, and founded in 2020. The company discovers and develops innovative medicines to address high unmet needs in various therapeutic areas, including oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Its pipeline features a diverse portfolio of uncorrelated programs ranging from preclinical to Phase 3 stages, such as SerpinPC targeting Hemophilia A and B, LB101 for solid tumors, ORX750 for Narcolepsy Type 1 and other sleep disorders, MGX292 for Pulmonary Arterial Hypertension, and additional undisclosed assets for solid tumors. ORX142, a novel Orexin Receptor 2 agonist, is advancing in clinical development with recent FDA clearance for Phase 1 studies. Centessa Pharmaceuticals plc focuses on delivering transformational therapies through its integrated platform, emphasizing orexin receptor agonists and other novel mechanisms to treat complex diseases like sleep disorders and beyond.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mario Alberto Accardi Ph.D.
Employees
129
Headquarters
Altrincham, United Kingdom

Frequently asked questions about Centessa Pharmaceuticals plc American Depositary Receipt